TranS1 Inc. Announces Preliminary Unaudited Fourth Quarter 2012 Revenue

TranS1 Inc. Announces Preliminary Unaudited Fourth Quarter 2012 Revenue

WILMINGTON, N.C., Jan. 14, 2013 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON),
a medical device company focused on designing, developing and marketing
products to treat degenerative conditions of the spine affecting the lower
lumbar region, today announced its preliminary unaudited revenue for the
fourth quarter ended December 31, 2012.

TranS1 expects revenues to be approximately $4.1 million in the fourth quarter
of 2012, representing a 3% increase from revenues of $4.0 million in the
fourth quarter of 2011 and a 29% increase from revenues of $3.2 million in the
third quarter of 2012. The fourth quarter of 2012 includes domestic revenue of
approximately $3.0M, a 4% increase over the third quarter of 2012, and
international revenue of approximately $1.1 million, primarily from the
initial stocking order for our new AxiaLIF® distributor in China.

The Company previously issued revenue guidance in the range of $3.8 - $4.2
million for the fourth quarter ending December 31, 2012.

"The return to revenue growth in the fourth quarter marks an important
milestone in our business as we begin to turn the corner and gain market share
with our minimally invasive technologies for spinal fusion," said Ken Reali,
President and Chief Executive Officer of TranS1. "2013 will be an important
year as we build the business utilizing the new Category I code for our
AxiaLIF technology."

About TranS1 Inc.

TranS1 is a medical device company focused on designing, developing and
marketing products to treat degenerative conditions of the spine affecting the
lower lumbar region. TranS1 currently markets the AxiaLIF family of products
for single and two level lumbar fusion, the VEO^TM lateral access and
interbody fusion system and the Vectre^TM posterior fixation system for lumbar
fixation supplemental to AxiaLIF fusion. TranS1 was founded in May 2000 and is
headquartered in Wilmington, North Carolina. For more information, visit
www.trans1.com.

Forward Looking Statements

This press release includes statements that are based on our current beliefs
and assumptions. These statements constitute "forward looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, and are intended to qualify for
the safe harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Such statements are subject to risks and
uncertainties that are often difficult to predict, are beyond our control, and
which may cause results to differ materially from expectations. Factors that
could cause our results to differ materially from those described include, but
are not limited to, the pace of adoption of our product technology by spine
surgeons, the outcome of coverage and reimbursement decisions by the
government and third party payors, the success of our continuing product
development efforts, the effect on our business of existing and new regulatory
requirements, uncertainty surrounding the outcome of the matters relating to
the subpoena issued to the Company by the Department of Health and Human
Services, Office of Inspector General, stockholder class action lawsuits, and
other economic and competitive factors. For a discussion of the most
significant risks and uncertainties associated with TranS1's business, please
review the Company's filings with the Securities and Exchange Commission,
including its Annual Report on Form 10-K for the year ended December 31, 2011
and subsequent reports. You are cautioned not to place undue reliance on these
forward looking statements, whichare based on TranS1's expectations as of the
date of this press release and speak only as of the date of this press
release. We undertake no obligation to publicly update or revise any forward
looking statement, whether as a result of new information, future events or
otherwise.

CONTACT: Investors:
         TranS1 Inc.
         Joseph P. Slattery, 910-332-1700
         Executive Vice-President and Chief Financial Officer
         or
         Westwicke Partners
         Mark Klausner, 443-213-0501
         trans1@westwicke.com
 
Press spacebar to pause and continue. Press esc to stop.